Carolyn R. Keeseman

Carolyn R. Keeseman serves as a Contracting Officer responsible for managing the acquisition of biological products, excluding diagnostic agents, within a federal procurement environment. Her role centers on ensuring compliance with federal acquisition regulations while delivering mission-critical biological manufacturing capabilities to support public health and scientific initiatives. She oversees the full lifecycle of contract actions—from market research and solicitation development to award and contract administration—focusing on complex, high-stakes procurements requiring stringent regulatory alignment and technical oversight. Her acquisitions typically involve research-grade materials, biomanufacturing services, and process development contracts requiring adherence to FDA standards and Good Manufacturing Practices. While specific contractor relationships are not publicly enumerated, Keeseman’s procurement patterns indicate consistent engagement with specialized manufacturers and contract development and manufacturing organizations (CDMOs) capable of producing sterile, GMP-compliant biological products. She works with vendors possessing validated production facilities, robust quality assurance systems, and demonstrated experience in aseptic processing and biologics scale-up. Her contracting approach emphasizes technical capability, regulatory compliance, and supply chain resilience over price alone, fostering long-term partnerships with qualified industry participants. Keeseman’s contracting portfolio reflects a strong preference for open competition, with 100% of her awards issued without set-aside designations. This indicates a focus on technical merit and capacity rather than socioeconomic categories, aligning with mission requirements that prioritize product integrity and manufacturing scalability over socioeconomic preferences. While she does not routinely utilize 8(a), HUBZone, or SDVOSB set-asides, her approach remains compliant with all statutory obligations and may incorporate small business subcontracting where technically appropriate. Her primary specialization lies in NAICS 325414—Biological Product (except Diagnostic) Manufacturing—where she procures vaccines, therapeutic proteins, cell and gene therapies, and other advanced biologics. Her expertise encompasses the unique regulatory, technical, and logistical demands of biological production, including cold chain management, biosafety containment, and process validation. Keeseman’s work directly supports national health security and biomedical innovation through precise, compliant procurement of mission-critical biological assets.